TH02 – Contested Spaces and Disrupted Markets: Controversies in the Struggle for Innovation and Control of Health and Medicines (July 9-11, 2022)
Call for Papers
Organized by Larry Au, Kathryn Ibata-Arens, Wan-Zi Lu, and Étienne Nouguez
More on the conference: https://sase.org/event/2022-amsterdam/#general
Health and medicines have become the center of controversy in recent years. From the transnational anti-vax movement, the diminishing authority of medical professionals, to the disputed efficacy of alternative and traditional medicines—controversies around claims of authority and accountability have affected the wellbeing of individuals and communities. Social scientists have analyzed causes of such contestations as rising mistrust, the politicization of science, misinformation and disinformation on social media, as well as broader discontents over marketization of medicine. Against this backdrop of controversy, stakeholders—such as patients, physicians, policymakers, and the pharmaceutical industry—have altered their health-seeking behaviors, clinical routines, and approach to regulating and developing new drugs.
Controversies also bring forth struggles between stakeholders, as each vie for control in setting the new norms and rules that govern these marketplaces. For example, physicians have turned to mobile and tele-health solutions in providing care. Meanwhile, these changes prompt questions over the quality of care and how to regulate clinical interactions. Likewise, activists and policy reformers have championed open innovation systems to increase production capacity of Covid-19 vaccines and access to essential medicines; but these attempts were met with resistance from those benefiting from the privatization of profits. But amidst these struggles, therein lies new possibilities for innovation to advance more equal and equitable visions of healthcare.
The MedHealth mini-conference convenes interdisciplinary panels around these controversies, struggles, and transformations in contested spaces and disrupted markets. We will facilitate critical discussion and reflection on participants’ works-in-progress. Some potential questions include:
- ANARCHY: How has the panic-buying of such drugs as ivermectin impacted the markets for these drugs? What is the lasting influence of Covid-19 on the authority of experts and medical professionals? How has misinformation and disinformation impacted perceptions of trust and health-seeking behaviors?
- ACTIVISM: When and where have patient organizations been able to cooperate with scientists and clinicians to develop new protocols for medical care? What is the role of citizen science in a predominantly market-driven system of biomedical innovation? How can (social) entrepreneurs, large firms, and other alliances and coalitions foster new norms in healthcare?
- COORDINATION: What are some causal mechanisms in improving, or undermining community health, for example, through policy and organizational strategy? How do frameworks and methods identify key actors and explain outcomes? In the context of global health, how can different stakeholders work to promote access to healthcare?
- CONTROL: How have states and healthcare organizations been effective (or ineffective, indifferent) in the pricing of medicines? What should be the responsibility, if any, of the global intellectual property rights regime as arbitrated by the World Trade Organization in limiting patents on living matter? What are the roles for regulation of markets for such boundary-products between medicine and health food as probiotics, herbals, and other dietary supplements?
We encourage submissions exploring theoretical and empirical analysis from the developed and developing world. In the spirit of innovation and creativity, the panels will have an interactive workshop format around discussant feedback and moderated audience participation.
TH02-01 – The Struggle for Equity in Healthcare Policy and Activism
Moderator: Wan-Zi Lu
- From “War on Diseases” to “War on Big Pharma”: The Movement for Pharmaceutical Transparency and the Politicisation of Healthcare Activism Theo Bourgeron and Susi Geiger, University College Dublin, Dublin, Ireland
- Health Policies and Industrial and Innovation Policies Aimed at the Health Sectors: A Comparison between Brazil and China Celio Hiratuka1, Thiago Noronha Sugimoto2, Fernando Sarti3 and Camila Veneo Fonseca1, (1)University of Campinas/Institute of Economics, Campinas, Brazil, (2)University of Campinas, Campinas, Brazil, (3)Universtiy of Campinas / Institute of Economics, Campinas, Brazil
- The (so far) Failed Global Movement to Fight Vaccine Apartheid Jonathan Shaffer, Boston University, Boston, MA
TH02-02 – Coordination or Control in the Organizations of Healthcare
Moderator: Kathryn Ibata-Arens
- “We Are All Vulnerable, We Are All Fragile”: COVID-19 As Opportunity for, or Constraint on, Health Service Resilience in Colombia? Simon Turner, University of los Andes, Bogota, Colombia
- What It Takes to Give (and Take): Familial Decision-Making of Deceased Organ Donation in Israel and Taiwan Wan-Zi Lu, University of Chicago, Chicago, IL
- Blockbuster Diagnostics – a Comparative Analysis of Changing Business Models in the Diagnostics Sector Stuart Hogarth, University of Cambridge, Cambridge, United Kingdom
- American Healthcare Spending: Power, Language, and the Pricing of Advanced Medical Technology Armando Lara-Millan, Department of Sociology, UC Berkeley, Berkeley, CA
TH02-03 – The Contested Politics of Scientific Expertise and Medical Authority
Moderator: Etienne Nouguez
- Fertile Markets: The Making of a Cross-Border Reproductive Care Market Eleni Tsingou, Copenhagen Business School, Frederiksberg, Denmark
- Long Covid and Trust in Science Larry Au, Cristian Capotescu, Gil Eyal and Gabrielle Finestone, Columbia University, New York, NY
- One Man’s Pill Is Another Man’s Poison. Ambivalence of Definitional Power: The Case of Breast Cancer Drugs in Russia Elena Berdysheva, National Research University Higher School of Economics, Moscow, Russian Federation
- Covid-19 and the Contentious Politics of Expertise. Expert Controversies and Collective Actors in Italy and France Riccardo Emilio Chesta, Scuola Normale Superiore, Firenze, Italy and Damiano De Facci, Université Paris Diderot, Paris, France
TH02-04 – Innovation and the State: Private Markets versus the Global Commons for Drugs and Essential Medicines
Moderator: Larry Au
- Making Monsters, Making Money: Biotechnology and Pharmaceutical Patents over Living Matter (Plant, Animal, Human) Kathryn Ibata-Arens, DePaul University, Chicago, IL
- Repurposing and Tinkering: How Open Source Vaccine Initiatives Alternatively Organize for Novelty Konstantin Hondros, University Duisburg-Essen, Duisburg, Germany and Milena Karin Leybold, University of Innsbruck, Innsbruck, Austria
- How Location Mediates Hallelujah Moments: Reflections from the Cell and Gene Therapy Industry Maki Umemura, Cardiff University, Cardiff, United Kingdom of Great Britain and Northern Ireland
- Marketization Is Not the Right Word: Exploring the Informal-Epistemic Work of Private Clinics in Russia Maria Denisova, Maastricht University, Maastricht, Netherlands
TH02-05 – Change and Continuity of Medical Innovation: The Architecture of Health Markets
Moderator: Kathryn Ibata-Arens
- Inventing the Medicine of the Microbiota : Boundary-Organization, Products Valuation and Market Architecture Etienne Nouguez, Sciences Po
- Masking up: How Changes in Market Supply, Evolving Scientific Knowledge and Public Health Policies Shape the Use of Masks in the Times of COVID-19 Ya-Ching Huang and Alya Guseva, Department of Sociology, Boston University, Boston, MA
- State Brokerage: Strategies for Engagement in Healthcare’s Emerging Global Markets Benjamin Hunter, University of Sussex, Brighton, United Kingdom and Brian Salter, King’s College London, London, United Kingdom